Methylprednisolone or Intravenous Immunoglobulin in Children with Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS)?

Welzel, et al. [1] recently published a randomized controlled trial (RCT) comparing the efficacy of methylprednisolone (MP) with intravenous immunoglobulin (IVIg) for COVID-19 associated pediatric inflammatory multisystem syndrome, also referred to as COVID-19 associated multisystem inflammatory syndrome in children (MIS-C). This study was necessitated by the helplessness associated with the condition, in the face of the COVID pandemic, coupled with the ray of hope offered by these medications, documented through physician experiences and observational studies.

Automated summary

A recent study compared the efficacy of methylprednisolone and intravenous immunoglobulin for pediatric inflammatory multisystem syndrome associated with COVID-19. The study revealed promising results, providing clinicians with new treatment options.